Palatin Technologies Presents at the Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG)
CRANBURY, N.J., April 29, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunction were presented at the American College of Obstetricians and Gynecologists (ACOG) 2014 Annual Clinical Meeting in Chicago, IL on Monday, April 28, …